论文部分内容阅读
目的:了解低水平HBsAg的慢性乙肝患者经干扰素干预后血清HBsAg水平的变化情况、临床意义、影响因素。方法:选择2009年3月-2012年3月我院门诊就诊的HBsAg水平在300S/CO(化学发光微粒子免疫检测方法)以下的慢性乙肝53例,在与患者充分沟通并经患者同意后,其中25例给以普通干扰素α-2b500万IU肌肉注射,隔日一次,疗程48周;27例定期随访。2组每12周随访1次,每次进行ALT、AST、TBIL、HBsAg、HBsAb的检查,干预组同时进行血细胞检查,24周进行腹部彩超检查。结果:12周时干预组HBsAg开始下降,24周时部分HBsAg阴转,48周时干预组部分出现HBsAg血清学转换。结论:HBsAg定量在一定程度上反应了体内cccDNA的水平,低水平HBsAg的慢性乙肝经干扰素治疗可以实现HBsAg的血清学转换。
Objective: To understand the changes of serum HBsAg level after interferon intervention in chronic hepatitis B patients with low-level HBsAg, its clinical significance and influencing factors. Methods: From March 2009 to March 2012, 53 patients with chronic hepatitis B whose HBsAg level was out of 300S / CO (chemiluminescence microparticle immunoassay) were selected in outpatient clinic of our hospital. After thorough communication with the patients and patient consent, 25 cases were given normal interferon α-2b 5 million IU intramuscular injection, every other day, the course of 48 weeks; 27 cases were followed up regularly. The 2 groups were followed up every 12 weeks. ALT, AST, TBIL, HBsAg and HBsAb were examined in each group. The intervention group also performed the blood cell examination at the same time and the abdominal ultrasonography at 24 weeks. Results: HBsAg began to decline in the intervention group at 12 weeks, and some HBsAg turned negative at 24 weeks. HBsAg seroconversion occurred in the intervention group at 48 weeks. Conclusion: The quantification of HBsAg reflects the level of cccDNA in vivo to a certain extent. The treatment of interferon with chronic hepatitis B with low level of HBsAg can achieve seroconversion of HBsAg.